- All wounds reached complete closure and remained closed at the 12-month follow up
- The mean time to closure was 7.8 weeks with a mean graft use of 7.0 grafts
- The mean 4-week percentage of wound area reduction was 69.4%
- There were no adverse events attributed to the use of Grafix
About GrafixGrafix is a cryopreserved placental membrane comprised of an extracellular matrix (ECM) rich in collagen, growth factors, and viable cells native to the tissue. Grafix is processed using Osiris' proprietary technology; it is flexible and conforming and designed for application directly to hard-to-treat acute and chronic wounds, including but not limited to diabetic foot ulcers, venous leg ulcers and thermal burns. About Osiris Therapeutics Osiris Therapeutics, Inc., based in Columbia, Maryland, is a world leader in researching, developing, and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world's first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine - including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO 4 ™, Cartiform ®, Grafix ®, TruSkin ™ and Stravix ™. Osiris, Grafix, Cartiform, TruSkin and Stravix are registered trademarks of Osiris Therapeutics, Inc. BIO 4 is a trademark of Howmedica Osteonics Corp.. More information can be found on the company's website, www.Osiris.com. (OSIR-G) Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements may generally be identified by the use of the words "may," "will," "expects," "anticipates," "believes," "estimates," and similar expressions, and involve a number of risks and uncertainties. For a variety of reasons, actual results may differ materially from those described in or contemplated by any such forward-looking statement. Examples of forward-looking statements may include, without limitation, statements regarding the anticipated efficiencies and advantages of products or services. Consequently, the reader is cautioned to consider all forward-looking statements in light of the risks to which they are subject.
For additional information, please contact:Diane SavoieOsiris Therapeutics, Inc.(443) 545-1834 OsirisPR@Osiris.com